MaxLinear (MXL) PT Raised to $31 at JPMorgan, After Co Raises Revenue Estimates And Completes Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MXL Hot Sheet
Price: $56.85 -11.13%
Rating Summary:
9 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
9 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
JPMorgan analyst Bill Peterson raised the price target on MaxLinear (NYSE: MXL) to $31.00 (from $26.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK304 at Goldman Sachs
- Pfizer (PFE) PT Raised to $40 at Argus
- Bayerische Motoren Werke AG (BMW:GR) (BMWYY) PT Lowered to EUR66 at HSBC
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
